UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Huntingtin interacting proteins are genetic modifiers of neurodegeneration

PLoS genetics, 2007-05, Vol.3 (5), p.e82

2007

Volltextzugriff (PDF)

A Large Scale Huntingtin Protein Interaction Network Implicates Rho GTPase Signaling Pathways in Huntington Disease

The Journal of biological chemistry, 2014-03, Vol.289 (10), p.6709-6726

2014

Volltextzugriff (PDF)

SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models

Cell chemical biology, 2016-07, Vol.23 (7), p.849-861

2016

Volltextzugriff (PDF)

Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons

Neurobiology of aging, 2012-03, Vol.33 (3), p.621.e17-621.e33

2012

Volltextzugriff (PDF)

IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome

The Journal of cell biology, 2009-12, Vol.187 (7), p.1083-1099

2009

Volltextzugriff (PDF)

Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models

Nature medicine, 2013-08, Vol.19 (8), p.1030-1038

2013

Volltextzugriff (PDF)

Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1

PloS one, 2011-01, Vol.6 (1), p.e16676

2011

Volltextzugriff (PDF)

Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke

Scientific reports, 2016-05, Vol.6 (1), p.25626-25626, Article 25626

2016

Volltextzugriff (PDF)

Experimental Models for Identifying Modifiers of Polyglutamine-Induced Aggregation and Neurodegeneration

Neurotherapeutics, 2013-07, Vol.10 (3), p.400-415

2013

Volltextzugriff (PDF)

Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay

Neurobiology of disease, 2011-07, Vol.43 (1), p.248-256

2011

Volltextzugriff (PDF)

Targeting mutant huntingtin for the development of disease-modifying therapy

Drug discovery today, 2012-11, Vol.17 (21-22), p.1217-1223

2012

Volltextzugriff (PDF)

The TBP-like Factor CeTLF Is Required to Activate RNA Polymerase II Transcription during C. elegans Embryogenesis

Molecular cell, 2000-09, Vol.6 (3), p.705-713

2000

Volltextzugriff (PDF)

Composite Primary Neuronal High-Content Screening Assay for Huntington’s Disease Incorporating Non-Cell-Autonomous Interactions

Journal of biomolecular screening, 2010-08, Vol.15 (7), p.806-819

2010

Volltextzugriff (PDF)

Contribution of the amino and carboxyl termini for PHA‐4/FoxA function in Caenorhabditis elegans

Developmental dynamics, 2005-10, Vol.234 (2), p.346-354

2005

Volltextzugriff (PDF)

TR-FRET-Based Duplex Immunoassay Reveals an Inverse Correlation of Soluble and Aggregated Mutant huntingtin in Huntington's Disease

Chemistry & biology, 2012-02, Vol.19 (2), p.264-275

2012

Volltextzugriff (PDF)

Methylation patterns in pap regulatory DNA control pyelonephritis-associated pili phase variation in E. coli

Cell, 1994-02, Vol.76 (3), p.577-588

1994

Volltextzugriff (PDF)

L20 Olesoxime targets calpain overactivation in models of huntington’s disease

Journal of neurology, neurosurgery and psychiatry, 2016-09, Vol.87 (Suppl 1), p.A96-A97

2016

Volltextzugriff (PDF)

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients

Proceedings of the National Academy of Sciences - PNAS, 2017-06, Vol.114 (23), p.E4676-E4685

2017

Volltextzugriff (PDF)

Suppressing aberrant GluN3A expression rescues NMDA receptor dysfunction, synapse loss and motor and cognitive decline in Huntington's disease models

Nature medicine, 2013-07, Vol.19 (8), p.1030-1038

2013

Volltextzugriff (PDF)

Identification and Evaluation of Small Molecule Pan-Caspase Inhibitors in Huntington's Disease Models

Chemistry & biology, 2010-11, Vol.17 (11), p.1189-1200

2010

Volltextzugriff (PDF)

Identification and Evaluation of Small Molecule Pan-Caspase Inhibitors in Huntington’s Disease Models

Chemistry & biology, 2013-05, Vol.20 (5), p.742-742

2013

Volltextzugriff (PDF)

Huntington interacting proteins are genetic modifiers of neurodegeneration

PLoS genetics, 2007-05, Vol.3 (5), p.689

2007

Volltextzugriff (PDF)

Specific binding of PapI to Lrp-pap DNA complexes

Journal of Bacteriology, 1995-11, Vol.177 (22), p.6449-6455

1995

Volltextzugriff (PDF)

Use of a two-color genetic screen to identify a domain of the global regulator Lrp that is specifically required for pap phase variation

Journal of bacteriology, 1998-03, Vol.180 (5), p.1224-1231

1998

Volltextzugriff (PDF)

Use of a Two-Color Genetic Screen To Identify a Domain of the Global Regulator Lrp That Is Specifically Required forpap Phase Variation

Journal of Bacteriology, 1998-03, Vol.180 (5), p.1224

1998

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(29)

Publikationsform

Sprache

Englisch
(33)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Huntingtin interacting proteins are genetic modifiers of neurodegeneration

A Large Scale Huntingtin Protein Interaction Network Implicates Rho GTPase Signaling Pathways in Huntington Disease

SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models

Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons

IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome

Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models

Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1

Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke

Experimental Models for Identifying Modifiers of Polyglutamine-Induced Aggregation and Neurodegeneration

Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay

Targeting mutant huntingtin for the development of disease-modifying therapy

The TBP-like Factor CeTLF Is Required to Activate RNA Polymerase II Transcription during C. elegans Embryogenesis

Composite Primary Neuronal High-Content Screening Assay for Huntington’s Disease Incorporating Non-Cell-Autonomous Interactions

Contribution of the amino and carboxyl termini for PHA‐4/FoxA function in Caenorhabditis elegans

TR-FRET-Based Duplex Immunoassay Reveals an Inverse Correlation of Soluble and Aggregated Mutant huntingtin in Huntington's Disease

Methylation patterns in pap regulatory DNA control pyelonephritis-associated pili phase variation in E. coli

L20 Olesoxime targets calpain overactivation in models of huntington’s disease

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients

Suppressing aberrant GluN3A expression rescues NMDA receptor dysfunction, synapse loss and motor and cognitive decline in Huntington's disease models

Identification and Evaluation of Small Molecule Pan-Caspase Inhibitors in Huntington's Disease Models

Identification and Evaluation of Small Molecule Pan-Caspase Inhibitors in Huntington’s Disease Models

Huntington interacting proteins are genetic modifiers of neurodegeneration

Specific binding of PapI to Lrp-pap DNA complexes

Use of a two-color genetic screen to identify a domain of the global regulator Lrp that is specifically required for pap phase variation

Use of a Two-Color Genetic Screen To Identify a Domain of the Global Regulator Lrp That Is Specifically Required forpap Phase Variation

Suchergebnisse filtern